StockNews.com Begins Coverage on Pieris Pharmaceuticals (NASDAQ:PIRS)

StockNews.com began coverage on shares of Pieris Pharmaceuticals (NASDAQ:PIRS) in a research note published on Sunday. The brokerage issued a hold rating on the biotechnology company’s stock.

Pieris Pharmaceuticals Stock Down 0.6 %

Shares of NASDAQ:PIRS opened at $11.93 on Friday. Pieris Pharmaceuticals has a 52-week low of $10.89 and a 52-week high of $80.80. The stock has a market cap of $14.76 million, a P/E ratio of -42.61 and a beta of 0.48. The business’s 50 day moving average is $13.87 and its 200 day moving average is $15.47.

Pieris Pharmaceuticals (NASDAQ:PIRS) last announced its quarterly earnings data on Friday, March 29th. The biotechnology company reported ($4.00) earnings per share (EPS) for the quarter. Pieris Pharmaceuticals had a negative return on equity of 90.17% and a negative net margin of 57.33%. The firm had revenue of $1.30 million during the quarter.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Summit Trail Advisors LLC purchased a new stake in shares of Pieris Pharmaceuticals during the 1st quarter valued at $26,000. Acadian Asset Management LLC lifted its holdings in shares of Pieris Pharmaceuticals by 64.8% during the 3rd quarter. Acadian Asset Management LLC now owns 962,358 shares of the biotechnology company’s stock valued at $286,000 after purchasing an additional 378,339 shares during the last quarter. Finally, CM Management LLC raised its stake in Pieris Pharmaceuticals by 18.1% in the 3rd quarter. CM Management LLC now owns 649,400 shares of the biotechnology company’s stock worth $194,000 after acquiring an additional 99,400 shares during the last quarter. Institutional investors own 40.11% of the company’s stock.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc, a biotechnology company, discovers and develops biotechnological applications. The company focuses on the development of its 4-1BB bispecifics immuno-oncology (IO) programs. Its clinical pipeline consists of IO bispecifics, including S095012 (PRS-344), a bispecific Mabcalin compound targeting PD-L1 and 4-1BB in partnership with Les Laboratoires Servier and Institut de Recherches Internationales Servier; SGN-BB228 (PRS-346), a CD228 x 4-1BB bispecific antibody-Anticalin compound targeting CD228 and 4-1BB in partnership with Pfizer Inc; and BOS-342 (PRS-342), a GPC3 x 4-1BB bispecific Mabcalin compound targeting GPC3 and 4-1BB in partnership with Boston Pharmaceuticals, which are in phase 1 studies.